The advertisement promotes Zejula, highlighting it as the only FDA-approved PARP inhibitor with statistically significant progression-free survival (PFS) in patients with HRD-positive advanced ovarian cancer.
Creative Information
| CID: | b0b0da3e-7411-4719-9516-0e770fdaad87 |
| CRID: | 82_2108-960770 |
| Domain: | gsk.com |
| Seat: | PP |
| Size: | 320x50 |
| Bid: | $5.70 |
| Timestamp: | 11/7/2025, 5:37:13 PM |
| Declared IAB Categories: |
Analysis
5 succeeded(100% complete)
| Task | Status | Last Updated | Duration | Actions |
|---|---|---|---|---|
| ad_analysis | success | 11/7/2025, 8:11:11 PM | 5.54s | |
| adomain_analysis | success | 11/7/2025, 8:40:49 PM | 4.22s | |
| adomain_capture | success | 11/7/2025, 8:40:43 PM | 0.16s | |
| ad_render | success | 11/7/2025, 8:11:06 PM | 24.60s | |
| brand_mapping | success | 11/7/2025, 5:37:14 PM | 0.11s | |
Analysis Results
Ad Format: banner
Brands: GlaxoSmithKline
Sensitive:Pharmaceutical Products
Quality:Adomain not match landing page domain
| Size: | 320x50 | ||||||||||||||||||||||
| Data Transferred: | 1386.23 KB | ||||||||||||||||||||||
| Render Time: | 9.04 Seconds | ||||||||||||||||||||||
| Creative Inferred IAB Categories: |
| ||||||||||||||||||||||
| Creative Inferred IAB Ad Products: |
| ||||||||||||||||||||||
| Domain Inferred IAB Categories: |
| ||||||||||||||||||||||
| Domain Inferred IAB Ad Products: |
| ||||||||||||||||||||||
| Landing Page: | |||||||||||||||||||||||
| Total Ad Size: | 1386.35 KB | ||||||||||||||||||||||
| Requests Made: |
|
Advertiser Domain

Ad Preview
Landing Page

Creatives
